In vitro data suggests small oral doses of aspirin can inhibit platelet prostaglandin production without substantially affecting aorta or coronary artery prostaglandin production.
Answers are grounded in this paper and cite their sources.
May support low-dose aspirin selectivity for platelets in vitro; leaves open in vivo translation and clinical outcomes.
The rate of acetylation of fatty acid cyclooxygenase (prostaglandin synthase, EC 1.14.99.1) by [acetyl-3H]-aspirin was measured in microsomes from human aortas and coronary arteries and intact and disrupted human platelets. We also measured the inhibition by aspirin of prostacyclin generation from exogenous arachidonic acid in shredded human aorta. Cyclooxygenase in human aorta and coronary artery microsomes is approximately 1/250th as sensitive to aspirin as enzyme in intact platelets, and 1/60th as sensitive to aspirin as enzyme measured in a platelet microsomal preparation. On the basis of the in vitro data presented, we predict that small oral doses of aspirin are sufficient to inhibit platelet prostaglandin production but are not sufficient to substantially affect aorta or coronary artery prostaglandin production.
No takes yet. Share an insight, caveat, or question.
Burch et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: